Filing Flows › CytomX Therapeutics (CTMX) › Stock forecast & fair value
CytomX Therapeutics (CTMX) stock forecast and price target
CytomX Therapeutics (CTMX) trades at $2.19. 8 analysts' median price target is $12.00 (+448%), from $6.00 to $16.00.
CytomX Therapeutics' latest quarter
CytomX Therapeutics, Q3 2026: revenue $1.7M (-72% year over year), net loss $20.0M, operating cash flow $16.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for CTMX stock?
The median of 8 analysts' 12-month targets is $12.00, +448% from $2.19; the range is $6.00 to $16.00. The average rating is none.
Does CytomX Therapeutics usually beat earnings estimates?
It beat the consensus EPS estimate in 40% of the quarters on record.
Is CTMX stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.